Microglia in pathological pruning of synaptic structures in Parkinson’s Disease and LDOPA induced dyskinesia models

FELIX FARES TAIE; AGOSTINA STAHL; CECILIA TUBERT; JESICA UNGER; DIEGO E. PAFUNDO; JUAN E. BELFORTE; IRENE RE. TARAVINI; LORENA RELA

CABA

Congreso; XXXVII SAN Annual Congress; 2022

Sociedad Argentina de Investigación en neurociencias

Parkinson’s disease (PD) results from thedopaminergic denervation of thestriatum, the main input to the basalganglia and a key structure for actionselection and initiation.Dopaminergic denervation changes theexcitability and structure of striatalmedium spiny neurons (MSN)differentially for each subtype (dMSN/iMSN), producing a disbalance inpathway recruitment, leading tohypokinesiaChronic L-DOPA therapy induces additionalplastic changes in MSNs from parkinsonianmice and is also associated with dyskinesia,known as L-DOPA-induced dyskinesia (LID).In neuroinflammation models, microglia canadopt reactive phenotypes.Antinflammatory drugs such as doxycylinediminishes microglial activation and providesneuroprotection in a variety of animal modelsof PD.